Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of effectiveness and safety of standard dose and low dose rivaroxaban in patients with atrial fibrillation

Trial Profile

Study of effectiveness and safety of standard dose and low dose rivaroxaban in patients with atrial fibrillation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
    • 02 Aug 2018 New trial record
    • 31 Jul 2018 Results published in the Journal of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top